Skip to main content
Faculty and Staff
Akhlaghi  

Fatemeh Akhlaghi, Pharm. D., Ph.D.

 

Associate Professor of Pharmacokinetics
Department of Biomedical and Pharmaceutical Sciences
fatemeh@uri.edu

Click here for information about Dr. Akhlaghi's lab
     

Research Interests

  
  • PK/PD of immunosuppressive agents in diabetic kidney transplant recipients
  • Therapeutic drug monitoring
  • Metabolism of statins in diabetes mellitus
  • PKPD modeling
     

Education

  

Ph.D., University of Sydney, Australia, 1996

Pharm.D., University of Mashhad, Iran, 1990
     

Experience

  

Associate Professor, College of Pharmacy, University of Rhode Island, USA; 2006-current

Assistant Professor, College of Pharmacy, University of Rhode Island, USA; 2001-2005

Senior Clinical Scientist, Pharmacology Clinical Research Unit, Addenbrooke's and Papworth Hospitals, University of Cambridge, United Kingdom; 1998-2000

Postdoctoral Research Associate, Faculty of Pharmacy, University of Sydney, Australia; 1996-1998
     
Selected Publications  

Pabla D, Akhlaghi F, Zia H.  A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. European Journal of Pharmaceutics and Biopharmaceutics 2008; Nov 1. [Epub ahead of print]

Mendonza AE, Gohh RY, Akhlaghi F.  Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients.  Clinical Pharmacokinetics 2008; 47(11):733-42.

Chitnis SD, Akhlaghi F. Development and validation of an HPLC-UV method for iodixanol quantification in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jun 15;869(1-2):133-7.

Patel CG, Richman K, Yang D, Yan B, Gohh RY, Akhlaghi F. Effect of diabetes on mycophenolic acid concentration and inosine monophosphate dehydrogenase activity in kidney transplant recipients. Ther Drug Monit; 29: 735-42 (2007).

Mendonza AE, Zahir H, Gohh RY, Akhlaghi F.  Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 29: 391-8 (2007).

Patel CG, Harmon M, Gohh RY, Akhlaghi F. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus. Ther Drug Monit, 29: 87-95 (2007).

Shi D, Yang J, Yang D, Lecluyse EL, Black C, You L, Akhlaghi F, Yan B.  Anti-influenza viral prodrug oseltamivir is activated by carboxylesterase HCE1 and the activation is inhibited by anti-platelet agent clopidogrel, J Pharmacol Exp Ther, 319: 1477-1484 (2006).